J. R. Fraser Cummings at University Hospital Southampton NHS Foundation Trust - Research Interests, Publications & Academic Profile

J. R. Fraser Cummings

University Hospital Southampton NHS Foundation Trust

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Vietnamese students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

20%

Internal Medicine

50%

Inflammatory Disease

70%

Graft-versus-host Disease

40%

Biologic Therapy

30%

Gastroenterology

30%

Anti-inflammatory Research

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

Establishing key performance indicators for inflammatory bowel disease in the UK

Article Link

Year:

2023

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial

Article Link

Year:

2023

Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study

Article Link

Year:

2023

Clinical impact of syndromic molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis (GastroPOC): a pragmatic, open-label, randomised controlled trial

Article Link

Year:

2023

Prediction of Crohn's Disease Stricturing Phenotype Using a NOD2-derived Genomic Biomarker

Article Link

Year:

2023

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Article Link

Year:

2022

Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.

Article Link

Year:

2022

A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence

Article Link

Year:

2022

Impact of direct-access IBD physician delivered endoscopy on clinical outcomes: a pre-implementation and post-implementation study

Article Link

Year:

2022

Patient perspectives of successful adalimumab biosimilar transitioning in Crohn's disease: an interview study

Article Link

Year:

2022

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]

Article Link

Year:

2022

Collaborators13

Anjan Dhar

Professor of Medicine, Consultant Gastroenterologist

UNITED KINGDOM

Nicholas Kennedy

Honorary Clinical Senior Lecturer

University of Exeter

UNITED KINGDOM

Dong-Hyeon Kim

Prof. Dr.

Konkuk University

SOUTH KOREA

Richard Hansen

Clinical Reader in Child Health

University of Dundee

UNITED KINGDOM

Nick Powell

Reader in Gastroenterology

Imperial College London

UNITED KINGDOM

Byong Duk Ye

Professor

University of Ulsan College of Medicine

SOUTH KOREA

Shaji Sebastian

UNITED KINGDOM

Clare Harris

University of Southampton

UNITED KINGDOM

Keith Bodger

University of Liverpool

UNITED KINGDOM

Craig Mowat

Academic, Clinical Sen Lecturer/Honorary Cons (Teaching and Research)

University of Dundee

UNITED KINGDOM

Jonathan Macdonald

University of Glasgow

UNITED KINGDOM

Christopher A. Lamb

UNITED KINGDOM

Paul Henderson

UNITED KINGDOM

How do Vietnamese students reach out?

Meet Kite AI